243 related articles for article (PubMed ID: 17120594)
21. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
[TBL] [Abstract][Full Text] [Related]
22. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients.
Planchon B; Pistorius MA; Beurrier P; De Faucal P
Angiology; 1994 Aug; 45(8):677-86. PubMed ID: 8048777
[TBL] [Abstract][Full Text] [Related]
23. A study of migraine in systemic lupus erythematosus.
Isenberg DA; Meyrick-Thomas D; Snaith ML; McKeran RO; Royston JP
Ann Rheum Dis; 1982 Feb; 41(1):30-2. PubMed ID: 7065726
[TBL] [Abstract][Full Text] [Related]
24. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S
Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388
[TBL] [Abstract][Full Text] [Related]
25. Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome.
Ferraccioli G; Di Poi E; Di Gregorio F; Giacomuzzi F; Guerra U
Lancet; 1999 Dec 18-25; 354(9196):2135-6. PubMed ID: 10609825
[TBL] [Abstract][Full Text] [Related]
26. [Multivariate analysis as a method of determination of anthropogenic load on the course of Raynaud's disease in patients with systemic scleroderma and systemic lupus erythematosus].
Kuchma GB; Bagirova VV; Setko NP
Ter Arkh; 2001; 73(5):37-9. PubMed ID: 11517745
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic value of thermography in Raynaud's phenomenon associated with systemic lupus erythematosus].
Mikulska D
Ann Acad Med Stetin; 2009; 55(3):23-7. PubMed ID: 20698174
[TBL] [Abstract][Full Text] [Related]
28. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
29. Association of Clinical Manifestations of Systemic Lupus Erythematosus and Complementary Therapy Use in Taiwanese Female Patients: A Cross-Sectional Study.
Lu MC; Hsu CW; Lo HC; Chang HH; Koo M
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888663
[TBL] [Abstract][Full Text] [Related]
30. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
[TBL] [Abstract][Full Text] [Related]
31. [Mucocutaneous lesions in patients with systemic lupus erythematosus].
Saurit V; Campana R; Ruiz Lascano A; Ducasse C; Bertoli A; Agüero S; Alvarellos A; Caeiro F
Medicina (B Aires); 2003; 63(4):283-7. PubMed ID: 14518140
[TBL] [Abstract][Full Text] [Related]
32. Association of neutrophil extracellular trap levels with Raynaud's phenomenon, glomerulonephritis and disease index score in SLE patients from Brazil.
Delabio Auer E; Bumiller-Bini Hoch V; Borges da Silva E; Ricci Zonta Y; Alarcão Dias-Melicio L; Larocca Skare T; F Picceli V; Messias-Reason IJ; Boldt ABW
Immunobiology; 2024 May; 229(3):152803. PubMed ID: 38640572
[TBL] [Abstract][Full Text] [Related]
33. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE.
Vitali C; Bencivelli W; Isenberg DA; Smolen JS; Snaith ML; Sciuto M; d'Ascanio A; Bombardieri S
Clin Exp Rheumatol; 1992; 10(5):527-39. PubMed ID: 1458709
[TBL] [Abstract][Full Text] [Related]
34. Severe Raynaud's phenomenon in a patient with antinuclear antibody-negative systemic lupus erythematosus.
Maxwell CJ; Potter E; Townsend J
J Natl Med Assoc; 1988 May; 80(5):594-5. PubMed ID: 3262169
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE.
Uhm WS; Lee HS; Chung YH; Kim TH; Bae SC; Joo KB; Kim TY; Yoo DH
Lupus; 2002; 11(4):227-33. PubMed ID: 12043886
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients.
Li EK; Tam LS
J Rheumatol; 1999 Sep; 26(9):1923-9. PubMed ID: 10493670
[TBL] [Abstract][Full Text] [Related]
37. [Raynaud's phenomenon: pathogenesis and prevalence].
Mikulska D
Ann Acad Med Stetin; 2010; 56(1):11-4. PubMed ID: 21427808
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus.
Vilá LM; Mayor AM; Valentín AH; García-Soberal M; Vilá S
Lupus; 2000; 9(2):110-5. PubMed ID: 10787007
[TBL] [Abstract][Full Text] [Related]
39. [Lupus erythematosus with muscular involvement and Raynaud's syndrome].
Gajkowski K
Neurol Neurochir Pol; 1974; 8(1):109-12. PubMed ID: 4135376
[No Abstract] [Full Text] [Related]
40. Raynaud's phenomenon with oral manifestation in systemic lupus erythematosus.
da Cunha Bang F; Lange Wantzin G; Dahl Christensen J
Dermatologica; 1985; 170(5):263-4. PubMed ID: 4007223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
